文献速递甲状腺疾病

活动期中重度甲状腺眼病静脉糖皮质激素治疗反应的相关因素

Factors Associated with Response to Intravenous Glucocorticoids in Active Moderate-to-Severe Thyroid Eye Disease.
PubMed 文献 · Thyroid · 2025-03-07

回顾性队列研究纳入64例活动期中重度甲状腺眼病(TED)患者,2003至2023年在单一三级中心接受12周EUGOGO方案静脉糖皮质激素(IVGC)治疗。治疗后6个月,临床判断(CL)评估的48/64(75%)和EUGOGO复合指数(CI)评估的32/44(73%)患者有反应。多变量分析显示,IVGC启动时年龄较大和治疗前临床活动度评分(CAS)较高与较差反应独立相关。

要点

  • IVGC启动时年龄较大与较差反应独立相关(CL评估OR=0.92,EUGOGO CI评估OR=0.88)。
  • 治疗前CAS较高与较差反应独立相关(CL评估OR=0.53,EUGOGO CI评估OR=0.08)。
  • 活动性吸烟未发现与IVGC反应独立相关。

核心结论

  • 年龄较大和治疗前CAS较高与IVGC反应较差相关。
  • 作者认为具有这些特征的患者可考虑其他免疫治疗作为活动期中重度TED的一线治疗。

研究设计与样本

  • 回顾性队列研究,纳入64例无甲状腺相关视神经病变的活动期中重度TED患者。
  • 患者于2003至2023年在单一三级中心接受12周EUGOGO方案IVGC治疗。
  • 所有患者按临床判断(CL)评估反应,其中44/64(69%)患者同时按EUGOGO 2021修订复合指数(CI)评估。

主要发现

  • IVGC启动时平均年龄51.7±11岁,47/64(73.5%)为女性,56/64(87.5%)为白种人,33/64(51.5%)为活动性吸烟者。
  • IVGC后6个月,CL评估的48/64(75%)患者和EUGOGO CI评估的32/44(73%)患者有反应。
  • 无反应者 tended to be older than responders(CL评估:56.6±10.2 vs. 50.1±10.8岁,p=0.040;EUGOGO CI评估:56.5±11.9 vs. 50.3±11.6岁,p=0.131)。
  • 无反应者IVGC前CAS较高(CL评估:5.0±1.1 vs. 4.2±1.1,p=0.022;EUGOGO CI评估:4.7±0.6 vs. 3.1±0.8,p<0.001)。
  • 多变量logistic回归显示,IVGC启动时年龄(CL评估OR=0.92 [95%CI 0.86-0.99],p=0.024;EUGOGO CI评估OR=0.88 [95%CI 0.77-0.99],p=0.046)和IVGC前CAS(CL评估OR=0.53 [95%CI 0.31-0.90],p=0.021;EUGOGO CI评估OR=0.08 [95%CI 0.01-0.38],p=0.001)为反应独立相关因素。

临床怎么用

  • 作者认为,具有年龄较大和治疗前CAS较高等特征的患者可考虑其他免疫治疗作为活动期中重度TED的一线治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Intravenous glucocorticoids (IVGCs) are the first-line treatment for active moderate-to-severe thyroid eye disease (TED) in many countries worldwide, mainly because of their anti-inflammatory efficacy. Methods: Retrospective cohort study of 64 patients with active moderate-to-severe TED, without dysthyroid optic neuropathy, treated between 2003 and 2023 at a single tertiary centre with the 12 weeks IVGC EUGOGO (European Group on Graves Orbitopathy) protocol. All patients were evaluated for response to IVGC according to the clinical judgment (CL) and 44/64 (69%) patients were also evaluated with the EUGOGO 2021 revised composite index (CI). Results: The mean patients' age at IVGC initiation was 51.7 ± 11 years, 47/64 (73.5%) were women, 56/64 (87.5%) were Caucasians, and 33/64 (51.5%) were active smokers. At 6 months after IVGC, 48 out of 64 (75%) patients evaluated with CL and 32 out of 44 (73%) patients evaluated with EUGOGO CI responded to the treatment. Nonresponders tended to be older than responders (56.6 ± 10.2 vs. 50.1 ± 10.8 years, p = 0.040 for CL and 56.5 ± 11.9 vs. 50.3 ± 11.6 years, p = 0.131 for EUGOGO CI) and had higher clinical activity score (CAS) before IVGC (5.0 ± 1.1 vs.4.2 ± 1.1, p = 0.022 for CL and 4.7 ± 0.6 vs. 3.1 ± 0.8, p < 0.001 for EUGOGO CI). In patients evaluated with CL or EUGOGO CI, respectively, multivariable logistic regression identified age at IVGC initiation (odds ratio [OR] = 0.92 [95% confidence interval (CI) 0.86-0.99], p = 0.024 and OR = 0.88 [CI 0.77-0.99], p = 0.046) and CAS before IVGC (OR = 0.53 [CI 0.31-0.90], p = 0.021 and OR= 0.08 [CI 0.01-0.38], p = 0.001) but not active smoking as independent factors associated with response to IVGC. The optimal cut-off associated with poorer response to IVGC was CAS ≥4.5/7 (66.7% specificity, 56.3% sensitivity; Area Under the Curve [AUC] = 0.689 [CI 0.54-0.83], p = 0.010) in patients evaluated with CL and CAS ≥3.5/5 (65.6% specificity, 91.7% sensitivity; AUC = 0.910 [CI 0.80-1.01], p < 0.001) in patients evaluated with EUGOGO CI. Conclusion: Older age and higher CAS before treatment were associated with poorer response to IVGC. Patients with these characteristics could be offered other immunotherapies as a first-line treatment for active moderate-to-severe TED.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Baczewska N, Alexopoulou O, Constantinescu SM, et al. Factors Associated with Response to Intravenous Glucocorticoids in Active Moderate-to-Severe Thyroid Eye Disease. Thyroid. 2025. PMID: 40053436. doi:10.1089/thy.2024.0629

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。